T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$3.46B |
| 2 |
UnitedHealth
UNH
|
+$2.79B |
| 3 |
Salesforce
CRM
|
+$2.38B |
| 4 |
Sherwin-Williams
SHW
|
+$1.41B |
| 5 |
Philip Morris
PM
|
+$1.34B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$4.44B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.97B |
| 3 |
GE Aerospace
GE
|
+$2.3B |
| 4 |
HCA Healthcare
HCA
|
+$2.17B |
| 5 |
American International
AIG
|
+$1.68B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.68% |
| 2 | Healthcare | 19.49% |
| 3 | Consumer Discretionary | 13.07% |
| 4 | Financials | 11.17% |
| 5 | Communication Services | 8.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
601
Origin Bancorp
OBK
$1.69B
| $124M | 0.02% |
3,183,565
-6,957
| -0.2% | -$274K |
|
602
Fate Therapeutics
FATE
$316M
| $123M | 0.02% |
4,983,503
+72,136
| +1% | +$1.99M |
|
603
Akamai
AKAM
$18.1B
| $123M | 0.02% |
1,343,531
-130,003
| -9% | -$13.5M |
|
604
PPG Industries
PPG
$25.6B
| $122M | 0.02% |
1,070,426
-59,881
| -5% | -$7.48M |
|
605
Infosys
INFY
$49.7B
| $122M | 0.02% |
6,610,116
-554,193
| -8% | -$11M |
|
606
Canadian Natural Resources
CNQ
$96.9B
| $122M | 0.02% |
4,654,196
-5,392,548
| -54% | -$164M |
|
|
AL
607
DELISTED
Air Lease Corp
AL
| $122M | 0.02% |
3,636,905
-133,327
| -4% | -$5.05M |
|
608
Lazard
LAZ
$4.3B
| $122M | 0.02% |
3,750,853
+462,677
| +14% | +$15.6M |
|
609
Zentalis Pharmaceuticals
ZNTL
$312M
| $121M | 0.02% |
4,298,551
+100,371
| +2% | +$2.66M |
|
610
Dorman Products
DORM
$3.95B
| $121M | 0.02% |
1,098,866
+229,438
| +26% | +$22.7M |
|
611
Texas Capital Bancshares
TCBI
$4.41B
| $120M | 0.02% |
2,278,954
+927,419
| +69% | +$49.7M |
|
612
Enerpac Tool Group
EPAC
$1.89B
| $120M | 0.02% |
6,283,852
-584,585
| -9% | -$11.8M |
|
613
West Fraser Timber
WFG
$5.55B
| $119M | 0.02% |
1,553,887
-72,308
| -4% | -$6.09M |
|
614
DoubleVerify
DV
$2.04B
| $119M | 0.02% |
5,229,072
+1,289,415
| +33% | +$29M |
|
615
Steel Dynamics
STLD
$37.6B
| $118M | 0.02% |
1,790,985
-21,290
| -1% | -$1.71M |
|
616
McCormick & Company Non-Voting
MKC
$14.6B
| $118M | 0.01% |
1,417,834
-74,231
| -5% | -$7.03M |
|
617
PAR Technology
PAR
$742M
| $118M | 0.01% |
3,139,470
+42,695
| +1% | +$1.53M |
|
618
Zegna
ZGN
$3.76B
| $117M | 0.01% |
11,132,721
+62,719
| +0.6% | +$642K |
|
|
SASR
619
DELISTED
Sandy Spring Bancorp Inc
SASR
| $117M | 0.01% |
2,986,559
+22,123
| +0.7% | +$904K |
|
|
TGI
620
DELISTED
Triumph Group
TGI
| $116M | 0.01% |
8,763,138
+52,167
| +0.6% | +$988K |
|
621
Onto Innovation
ONTO
$20.7B
| $116M | 0.01% |
1,666,438
+592,920
| +55% | +$43.9M |
|
622
State Street Industrial Select Sector SPDR ETF
XLI
$34.6B
| $115M | 0.01% |
+1,316,081
| New | +$124M |
|
|
RNAM
623
DELISTED
Avidity Biosciences
RNAM
| $115M | 0.01% |
7,883,125
-102,410
| -1% | -$1.52M |
|
624
Champion Homes
SKY
$5.15B
| $115M | 0.01% |
2,415,024
+162,051
| +7% | +$8.36M |
|
625
Aurora
AUR
$13.6B
| $114M | 0.01% |
59,776,350
+4,050,096
| +7% | +$14.9M |
|
Similar funds
T. Rowe Price Associates's Q2 2022 Portfolio in Review
As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
- T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
- T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
- T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
- T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
- T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.
Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.